Activation of Fibrinolysis System at the Main Arterial and Venous Vessels Thrombosis with the Treatment of Gene-Engineering Thrombolythic Drug ‘Triasa’

Abstract number: P1958

Kruchinsky¹ N, Plenina² L, Akulich¹ N, Tepljakov¹ A, Tsymanovich² S

¹¹Research Institute for Ecopathology and Occupational Diseases, Mogilev, Republic of Belarus ¹¹Research Institute for Ecopathology and Occupational Diseases, Mogilev, Republic of Belarus ²²‘Dialeck Ltd.’, Minsk, Republic of Belarus

Goal:  The purpose of the present research was studying safety and efficiency domestic gene-engineering Drug for thrombolysis ‘Triasa’ at carrying out of clinical tests (GCP) at 20 patients with thromboses main (arterial and venous) vessels.

Objectives and methods:  'Triasa’ represents the albuminous complex (active substance – the enzyme triasa) received and cleared from cell-culture of a liquid imperfect saprophytic of mushroom ‘Trichothecium rozeum’. This Drug for thrombolysis possesses activated fibrinolytic, thrombolytic and anti-inflammatory action, plasminogen activated, transforming it in plasmin, and renders direct fibrinolytic action. Prior to the beginning of carrying out of clinical tests of preparation ‘Triasa’ a series of experiments in vitro with use of blood of 22 volunteers for revealing an optimum doze of ‘Triasa’ has been lead. At each volunteer got on 50.0 ml of blood with subsequent its division on 10.0 ml, in which the ‘Triasa’ in various (3, 15, 150, 300 and 600 U/ml) concentration was added. Haemostasis System state research was spent before addition the drug (an initial condition), in 30 and 60 minutes after its addition in blood. The haemostasis was studied using evaluation of the platelet aggregation, coagulation, anticoagulant and fibrinolysis activity (25 parameters).

Results:  The lead research in vitro has shown, that the optimal concentration of a preparation ‘Triasa’ for achievement of a comprehensible level to the fibrinolytic activity, not resulting in failure haemostasis imbalance it is possible to count 150 U/ml. The lead researches have shown good bearableness of ‘Triasa’ without the complications. ‘Triasa’ infusion in a doze of 200 000–500 000 U was promoted knocking over of hypercoagulation (statistically reliable APTT, decrease in fibrinogen concentration and D-dimers) state and fibrinolytic potential (statistically reliable of euglobulin fibrinolysis) activation.

Conclusion:  Clinical tests (GSP) of ‘Triasa’ can be continued at a heart attack of a myocardium.